Epic Code LAB3581 MLH1 Promoter Hypermethylation
Test Name Alias
mutL homologue 1 | 7091
Interface Order Alias
55044
Quick Collect
Tissue/Other = LOOK+LOOK Paraffin Block = Mark Tumor and Normal
Clinical Information
Tissue sections are examined by a pathologist to scribe relevant tumor. Pyrosequencing is used to detect methylation status in the promoter region of MLH1 gene. This test is performed to follow up a positive Lynch Syndrome screening testing by MSI/IHC. When the MLH1 promoter methylation is detected (positive), the tumor is very likely sporadic in nature. When the MLH1 promoter methylation is not detected (negative), the cancer may be hereditary in nature, and a referral to cancer genetics is indicated.
Specimen Requirements
Specimen Type: Formalin-fixed, paraffin-embedded (FFPE) tissue (block or 10 unstained slides) accompanied by an H&E slide scribed by Pathologist indicating tumor and ATL Surgical Specimen Testing order sheet.
Specimen Transport Temperature
Ambient
Specimen Stability
Laboratory Retention: Extracted DNA retained greater than 1 year
Reflex Information
Mandatory Reflex Information:
Immunohistochemical (IHC) Stain – All newly diagnosed patients with endometrial cancer: If MLH1 absent
Test Frequency
Available once per week (Monday – Friday), usual TAT less than 7 days
Reference Range
An interpretative report will be provided
Performing Department
Molecular Diagnostics
Performing Department Laboratory Location
Corewell Health Advanced Technology Laboratory (ATL), Grand Rapids, MI
Methodology
Pyrosequencing
CPT
81288
CDM Code
3108128801
Epic Test ID
1230100949
Mayo Access Code
SHO55044
Reviewed Date
6/22/2023